SML3799

Nilotinib

≥98% (HPLC)

• Sinónimos: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide, 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide, AMN 107, AMN107
• Fórmula empírica (notación de Hill): C₂₈H₂₂F₃N₇O
• Número de CAS: 641571-10-0
• Peso molecular: 529.52
• MDL number: MFCD09833716
• UNSPSC Code: 12352200
• NACRES: NA.21

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (Warmed)
• storage temp.: 2-8°C

Descripción

Biochem/physiol Actions

Nilotinib (AMN107) is an orally available, selective and potent ATP-competitive wild-type and mutant Bcr-Abl kinase inhibitor that is 10-30-fold more potent than imatinib. Nilotinib is used to treat Philadelphia chromosome (Ph+)-positive chronic myelogenous leukemia (CML). Nilotinib reduces midbrain Bcr-Abl autophosphorylation, amyloid-β levels, and neuronal loss, as well as improves autophagosome clearance and reverses cognitive deficits in the Tg2576 transgenic mouse model of Alzheimer’s disease.

Información de seguridad

• pictograms: GHS08
• signalword: Danger
• hcodes: H372,H413
• pcodes: P260 - P264 - P270 - P273 - P314 - P501
• Hazard Classifications: Aquatic Chronic 4 - STOT RE 1
• target_organs: Liver,Kidney,gallbladder
• Storage Class: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk_germany: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable